About The Study: In this prespecified secondary analysis of the Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) prospective randomized trial, the overall lived experience of women randomized to undergo active monitoring for low-risk ductal carcinoma in situ was similar to that of women randomized to guideline-concordant care during the 2 years following diagnosis.
Corresponding Author: To contact the corresponding author, Ann H. Partridge, MD, MPH, email ann_partridge@dfci.harvard.edu .
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamaoncol.2024.6556)
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Media advisory: This study is being presented at the San Antonio Breast Cancer Symposium.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2024.6556?guestAccessKey=0eeee72d-bf97-4638-861c-42bfa16a41a5&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=121224
JAMA Oncology